Related Experiment Video
Updated: Mar 26, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
CANCER MUCOSA ANTIGENS A NOVEL PARADIGM IN CANCER IMMUNOTHERAPEUTICS
Adam E Snook1, Scott A Waldman1
1Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia PA 19107.
Abstract:
Employing antigens with expression restricted to normal intestinal mucosa and derivative colorectal tumors - cancer mucosa antigens (CMAs) - represents a novel paradigm in anti-tumor immunotherapy. Immune compartmentalization limits tolerance to CMAs and restricts mucosa-targeted autoimmunity, allowing safe and effective immunotherapy for metastatic colorectal cancer. Guanylyl cyclase C (GCC), an intestine/colorectal cancer-restricted protein, is poised for clinical evaluation as the index CMA.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
The Tumor Microenvironment
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...